Oxford immunotec global plc (OXFD)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities
Net loss

-1,809

120,779

-32,885

-22,349

-24,478

-22,174

-8,664

-14,883

Less: Net income (loss) from discontinued operations, net of tax

-469

108,274

341

-771

-

-

-

-

Net income (loss) from continuing operations

-1,340

12,505

-33,226

-21,578

-

-

-

-

Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation and amortization expense

1,753

1,662

1,618

932

-

-

-

-

Non-cash rent expense

247

-

-

-

-

-

-

-

Non-cash interest

184

-

-

-

-

-

-

-

Intangible assets impairment charges

-

879

-

-

-

-

-

-

Depreciation and amortization of intangible assets

-

-

-

-

2,142

1,742

1,101

801

Change in fair value of contingent purchase price consideration

-

-

-3,475

-1,208

202

72

0

-

Write-off of contingent purchase price consideration

-

-

-

-

-

0

-

-

Intangible assets impairment charges

-

-

18,300

1,765

419

0

0

-

Accretion and amortization of loan fees

-

2,408

569

-

0

-

-

-

Share-based compensation expense

3,613

4,507

5,671

4,901

3,485

2,521

140

79

Loss on change in fair value of warrants

-

-

-

-

-

22

279

-

Loss on change in fair value of derivative instrument

-

-

-

-

-

-

-561

-

Loss on disposal of property and equipment

-49

-115

-298

-

-33

0

1

-71

Deferred income taxes

-38

-38,760

1,602

-

0

-

-

-

Changes in operating assets and liabilities:
Noncash interest expense

-

-

-

-

-

-

-

1,425

Accounts receivable, net

4,263

3,390

988

1,642

416

2,311

-637

3,103

Inventory, net

2,826

1,015

1,768

1,486

893

1,214

2,808

1,045

Prepaid expenses and other assets

-1,386

-207

454

3,063

898

594

881

333

Accounts payable

-360

-10,375

-5,502

-7,326

1,363

-109

483

196

Accrued liabilities

-5,093

3,252

509

3,069

2,742

696

2,947

1,608

Settlement liability

-

-

-

-

0

-

-

-

Other liabilities, net

-

-4,209

3,733

-36

-

-

-

-

Deferred income

-107

95

-9

-1,639

-250

572

587

814

Net cash used in operating activities from continuing operations

-7,163

-32,119

-13,122

-27,311

-

-

-

-

Net cash used in operating activities

-

-

-

-

-16,549

-20,777

-5,619

-14,370

Cash flows from investing activities
Purchases of property and equipment

1,658

5,350

1,295

856

3,425

3,014

1,809

1,482

Purchases of intangible assets

-

-

-

-

43

354

205

79

Cash paid for acquisitions, net of cash acquired

-

-

-

27,515

0

1,716

0

-

Proceeds on sales of property and equipment

-

-

-

-

34

0

22

-

Change in restricted cash

-

-

-

-

-312

-57

-225

315

Net cash used in investing activities from continuing operations

-1,658

-5,350

-1,295

-28,371

-

-5,027

-1,767

-

Net cash used in investing activities

-

-

-

-

-3,122

-

-

-1,876

Cash flows from financing activities
Proceeds from revolving line of credit

-

-

-

-

-

-

-

1,500

Proceeds from convertible note

-

-

-

-

-

-

4,842

4,000

Proceeds received in advance of share issuance

-

-

-

-

-

-

-

8,075

Proceeds from issuance of ordinary shares

-

-

39,298

-

53,763

0

63,879

-

Proceeds from exercise of share options

4,035

3,241

561

76

20

14

-

-

Payments of tax withheld on exercises of options and vesting of restricted share units

224

383

212

-

0

-

-

-

Repurchases of ordinary shares

6,992

-

-

-

-

-

-

-

Payments on capital lease

-

60

261

80

-

-

-

-

Proceeds from term loan, net

-

-

-

29,457

0

0

6,582

-

Discount on the line of credit

-

-

-

50

0

0

-

-

Debt issuance costs

-

-

-

289

0

0

-

-

Loss on extinguishment of debt

-

-2,105

-

-

-

-

-

-

Change in loans payable

-

-30,000

-

-

-122

-

-

-

Proceeds from issuance of preferred ordinary shares

-

-

-

-

-

-

2,942

12,701

Proceeds from exercise of share options and warrants

-

-

-

-

-

-

22

1

Payments on loan

-

-

-

-

-

165

6,068

60

Net cash provided by (used in) financing activities from continuing operations

-3,181

-29,307

39,386

29,114

-

-

-

-

Net cash flows of continuing operations

-12,002

-66,776

24,969

-26,568

-

-

-

-

Cash flows from discontinued operations
Net operating cash flows provided by discontinued operations

-

14,729

9,548

5,401

-

-

-

-

Net investing cash flows used in discontinued operations

-

156,218

-3,734

-1,527

-

-

-

-

Net financing cash flows used in discontinued operations

-

-48

-12

-11

-

-

-

-

Net cash flows of discontinued operations

-

170,899

5,802

3,863

-

-

-

-

Payments on revolving line of credit

-

-

-

-

-

-

1,500

-

Net cash provided by financing activities

-

-

-

-

53,661

-151

70,699

26,217

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

428

-1,711

451

-1,780

-

-

-

-

Net decrease in cash, cash equivalents, and restricted cash

-11,574

102,412

31,222

-24,485

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-440

-374

603

273

Net increase (decrease) in cash and cash equivalents, excluding restricted cash

-

-

-

-

33,550

-26,329

63,916

10,244

Supplemental disclosures
Cash received (paid) for interest

4,071

-2,656

-

-

-

-

-

-

Cash paid for interest

-

-

3,123

450

41

-

-

-

Cash paid for taxes

-

-

145

141

50

-

-

-

Cash paid for interest

-

-

-

-

-

50

240

81

Cash paid for taxes

-2,702

-76

-

-

-

115

70

-281

Fair value of warrant issued with convertible note

-

-

-

-

-

-

296

-

Interest on convertible notes settled with G preferred ordinary shares

-

-

-

-

-

-

-

90

Warrants liability reclassified to additional paid-in capital upon exercise of warrants

-

-

-

-

-

318

0

-